SPRING PHARMACEUTICAL GROUP, INC. - FORM 10-K - EX-32 - CERTIFICATE PURSUANT TO 18 U.S.C. SS. 1350 - June 29, 2017

Attached files

file filename
EX-31.2 - RULE 13A-14(A) CERTIFICATE ? CFO - SPRING PHARMACEUTICAL GROUP, INC.exh31_2.htm
EX-31.1 - RULE 13A-14(A) CERTIFICATE ? CEO - SPRING PHARMACEUTICAL GROUP, INC.exh31_1.htm
EX-10.16 - RENEWAL OF THE PURCHASE AND SALE CONTRACT WITH SHANDONG YONGCHUNTANG DATED AS OF - SPRING PHARMACEUTICAL GROUP, INC.exh10_16.htm
10-K - 10K - SPRING PHARMACEUTICAL GROUP, INC.china.htm
EXHIBIT 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of China YCT International Group, Inc. (the "Company") on Form 10K for the period ending March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 29, 2017 
  
   
 
By:/s/ Yan Tinghe
  Yan Tinghe
Principal Executive Officer
 Date: June 29, 2017 
  
   
 
By:/s/ Li Chuanmin
Li Chuanmin
Principal Financial Officer
 
                                           
 

SPRING PHARMACEUTICAL GROUP, INC. Reports